PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab-cmkb Sensitive: A1 - Approval margetuximab-cmkb Sensitive : A1	margetuximab-cmkb Sensitive: A1 - Approval margetuximab-cmkb Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	Sensitive: A1 - Approval Sensitive : A1	Sensitive: A1 - Approval Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1

Breast Cancer

Associations(2430)

Associations
(2430)